Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0A3FZ
|
|||
| Former ID |
DNCL002782
|
|||
| Drug Name |
Rilimogene galvacirepvec
|
|||
| Synonyms |
Prostvac (TN)
Click to Show/Hide
|
|||
| Indication | Prostate cancer [ICD-11: 2C82.0; ICD-10: C61; ICD-9: 185] | Phase 3 | [1] | |
| Company |
BM ImmunoTherapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Prostate specific antigen (KLK3) | Target Info | Modulator | [1] |
| KEGG Pathway | Pathways in cancer | |||
| Prostate cancer | ||||
| Pathway Interaction Database | Coregulation of Androgen receptor activity | |||
| Regulation of Androgen receptor activity | ||||
| FOXA1 transcription factor network | ||||
| Reactome | Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) | |||
| Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 | ||||
| WikiPathways | Prostate Cancer | |||
| Androgen receptor signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Overall survival analysis of a phase II randomized controlled trial of a Poxviral-based PSA-targeted immunotherapy in metastatic castration-resistant prostate cancer. J Clin Oncol. 2010 Mar 1;28(7):1099-105. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.